A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

This study is testing a new experimental drug called IDE-161 to see how well it works, either alone or combined with an immunotherapy drug, to treat various types of advanced cancer. The goal is to see if this treatment can stop cancer cells from repairing their own DNA, which may help slow or stop tumor growth.

This study is for adults with advanced cancers—such as breast, ovarian, prostate, or lung cancer—that have spread. To join, your cancer must have specific genetic patterns or mutations related to how cells repair DNA, which your doctor will check through specialized tests.

Participants will receive the study medication and be closely monitored by a medical team to track how the body reacts to the drug and how well it treats the cancer. You will have regular check-ups, including physical exams and tests, to ensure your safety throughout the process.

The study currently has locations in Los Angeles and Newport Beach, California, as well as Denver, Colorado. While the study is active, it is currently not recruiting new participants.